MiRXES is a privately held life science research tool provider and miRNA diagnostic test developer headquartered in Singapore. MiRXES was founded by Professor Too Heng-Phon and three like-minded partners in 2014 with the vision of creating accurate, affordable and actionable molecular diagnostic tests to improve cancer management.
MiRXES is a spin-off from the Bioprocessing Technology Institute of the Agency of Science Technology And Research (A*STAR) and is supported by Exploit Technologies and the National University of Singapore. MiRXES collaborates extensively with academic, clinical and industrial partners locally and globally in advancing the science and business of miRNA. MiRXES is a key partner to Singapore’s National Diagnostic Initiative.
Lihan cofounded MiRXES. As CEO, Lihan currently oversees the company’s daily operation and product development. Prior to joining MiRXES, Lihan led the research team at the MicroRNA Signature Identification Center under A*STAR. Lihan has over six years of experience in qPCR technology development and biomarker discovery and is one of the three inventors of MiRXES’ core miRNA technology and know-hows. Lihan was trained as a molecular neurobiologist with a broad mastery in other biotechnology domains including gene delivery and tumor targeting nanoparticles. He received his Ph.D. in Biochemistry from the National University of Singapore with 16 publications and two patent applications. Lihan was honoured as an Innovators Under 35 (Asia) by MIT Technology Review in 2015.
Ruiyang cofounded MiRXES. As CTO, Ruiyang is primarily responsible for MiRXES’ technology and diagnostic test development. Ruiyang also oversees MiRXES’ China operation. Prior to joining MiRXES, Ruiyang was the head of bioinformatics the MicroRNA Signature Identification Center under A*STAR. He co-authored more than ten publications and has eight patents and applications. Ruiyang is one of the three inventors of MiRXES’ core miRNA technology and know-hows. Ruiyang has a double degree in science and engineering (B.S. in chemistry and B.E. in chemical engineering). He received his Ph.D. in Chemical and Pharmaceutical Engineering from the Singapore-MIT Alliance, National University of Singapore. In addition to miRNA, Ruiyang has developed multiple technologies in the field of metabolic engineering and synthetic biology.
Tani has been working with the MiRXES team in his previous capacity as the Senior Vice President and Head of the Biomedical Sciences Division at ETPL, the strategic marketing and commercialisation arm of A*STAR since 2010. As CBO, Tani is responsible for business development, collaborations and intellectual property management. Prior to joining MiRXES, Tani had a balanced career spanning 20+ years in academia, government as well as industry. He held research positions at the Joslin Diabetes Center, Harvard Medical School and the Genetic Immunotherapy Laboratory at the Division of Johns Hopkins in Singapore. He also held product development positions at Genelabs Diagnostics and Merck (EMD). At ETPL, Tani led a team of 22 officers and was responsible for the commercialization of A*STAR’s Biomedical technologies.
Doreen is the general manager for MiRXES. Prior to joining MiRXES, Doreen served several years in Corporate Managerial, Sales & Marketing leadership roles in biomedical companies, bioscience start-ups and academic research institutes. In total, Doreen brings over 15 years of corporate leadership experience to MiRXES. Doreen received her M.Sc in Molecular Biology from Nanyang Technological University, Singapore, B.Sc in Bacteriology from University of Wisconsin-Madison and Graduate Diploma in Business Administration from Singapore Management of Institute.
Too Heng Phon received his undergraduate and postgraduate training in Biochemistry at the Imperial College of Science & Technology, UK. He continued with his training in the Medical Research Council, Cambridge (UK) and the Harvard Medical School. He is currently a faculty in the Department of Biochemistry and an Adjunct of the Chemical & Biomolecular Engineering Department, National University Singapore.Dr Too is also a Principal Scientist in the Bioprocess Technological Institute, A*STAR and a Fellow of the Singapore Massachusetts Institute of Technology Alliance (Molecular Engineering of Biological & Chemical Systems program; Chemical & Pharmaceutical Engineering program). He is a molecular biologist focusing on biotechnology and neuroscience. He has been funded by Roche Diagnostics (USA & Asia Pacific) and the National Institute of Health (USA) to develop qPCR assays for infectious diseases. He has a number of intellectual property protections on specific diagnostic platforms with various research departments and with Massachusetts Institute of Technology, USA.
Dr Yeoh is a practicing Senior Consultant at the Department of Gastroenterology and Hepatology, National University Hospital (NUH). Dr Yeoh’s research interests are gastric and colorectal cancers. He is the Principal Investigator of the Singapore Gastric Cancer Consortium, a national flagship research group. He has published over 110 peer-reviewed papers in international journals. He also chairs the National Colorectal Cancer Screening Committee of the Health Promotion Board, Ministry of Health, which recommends guidelines for the national colorectal screening programme in Singapore.Dr Yeoh received his MBBS (Bachelor of Medicine, Bachelor of Surgery) from NUS in 1987. He was trained in internal medicine and gastroenterology at NUH. He is a Fellow of the Academy of Medicine, Singapore, Fellow of the Royal College of Physicians of London and Glasgow, and a member of the American Gastroenterology Association and American Society of Gastrointestinal Endoscopy. He also serves as a reviewer for several journals and grant funding agencies.
Dr Matter is best known for his contribution to the development of Glivec/Gleevec, one of the world’s first tyrosine kinase inhibitor drugs for cancer therapy. He led a team of around 200 scientists at Novartis to discover and optimize the lead compound, bringing it all the way through its first clinical trial in 1998. In a short span of 3 years, Gleevec was given a rare, fast track FDA approval in 2001.Prior to ETC, Dr Matter was the founding director for the Novartis Institute for Tropical Diseases (NITD) in 2003. Under his leadership, NITD successfully implemented research programs in the areas of dengue fever, tuberculosis and malaria attracting major grants from the Bill&Melinda Gates Foundation and the Wellcome Trust.A medical doctor by training, Dr. Matter received his medical degree from the University of Basel and did immunology and pathology research in Switzerland, Britain, France and the US before entering into the pharmaceutical industry. He has published more than 100 scientific articles plus several book chapters in the area of oncology and hematology. He is the recipient of the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award.
Prof Kong-Peng Lam obtained his BA (summa cum laude) at the University of Minnesota and his M.A., M.Phil and PhD at Columbia University in the USA. Thereafter he joined the Institute for Genetics at the University of Cologne in Germany as a postdoctoral research scientist, where he was awarded both the EMBO and HFSP long-term fellowships to study B cell development using conditional gene knockout approaches. He returned to Singapore in 1998 and assumed the position of Principal Investigator at the Institute of Molecular and Cell Biology (IMCB). In 2002-3, he attended the Sloan Fellow Program at Stanford University Graduate School of Business where he graduated with an MSc (Mgmt) degree.He was seconded to A*STAR Biomedical Research Council where he served as Director (2003), Deputy Executive Director (2004) and Acting Executive Director (2005-2006) while concurrently heading a research laboratory at the Center for Molecular Medicine (CMM). He returned to full-time research in October 2006 and was the founding Executive Director of the Singapore Immunology Network (SIgN), a post he held from 2006 to 2008. He joined the Bioprocessing Technology Institute (BTI) as Scientific Director in May 1 2008, and is currently its Executive Director. Kong-Peng also holds tenured Full Professorship at the National University of Singapore and Adjunct Full Professorship at the Nayang Technological University and sits on various BMRC and NMRC grant review committees. He was awarded the Arthur Kornberg Memorial Medal by the Asia-Pacific International Molecular Biology Organisation in November 2010.